Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report

Figure 2 Abdominal computed tomography and magnetic resonance during the treatment and follow-up. A: Magnetic resonance imaging done at the baseline before starting the therapy showed three liver lesions, with the largest measuring 527 cm; B: Magnetic resonance imaging performed after 2 cycles of first-line therapy showed a significant reduction in the liver lesions; C: Contrast-enhanced computed tomography (CT) done after 4 cycles of first-line therapy; D: Contrast-enhanced CT after 6 cycles of first-line therapy; E: Contrast-enhanced CT after 2 cycles of maintenance treatment; F: Contrast-enhanced CT done on August 8, 2024, after 6 cycles of maintenance treatment, showing sustained partial response; G: Contrast-enhanced CT done on March 7, 2025, after 6 months of treatment interruption. Oranges arrows indicate the primary lesions.